research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
=== Neurological === Chronic headaches are common in patients with Ehlers–Danlos syndrome, whether related to dysautonomia, temporomandibular joint dysfunction (TMD), muscle tension, tethered cord syndrome, craniocervical instability, and alantoaxial instability. Arnold–Chiari malformation is also more frequently found in patients with EDS because of the instability at the juncture between skull and spine. This causes herniation of the posterior fossa below the foramen magnum. Ligaments in the neck are unable to heal properly, so the neck structure cannot support the skull, which can then sink into the brainstem, blocking the flow of cerebrospinal fluid, which in turn causes autonomic dysfunction. Increased pressure created by the malformation can lead to a flattened pituitary gland, hormone changes, sudden severe headaches, ataxia, and poor proprioception. Ophthalmological manifestations include nearsightedness, retinal tearing and retinal detachment, keratoconus, blue sclera, dry eye, Sjogren's syndrome, lens subluxation, angioid streaks, epicanthal folds, strabismus, corneal scarring, brittle cornea syndrome, cataracts, carotid-cavernous sinus fistulas, and macular degeneration. Otological complications may also occur. Hearing loss is common, both conductive and sensorineural, and is most often bilateral. Otosclerosis and instability of the bones in the inner ear may also contribute to hearing loss.
Bird skeletons are very lightweight. Their bones are smaller and thinner than those of mammals, to aid flight. Among mammals, bats come closest to birds in terms of bone density, suggesting that small dense bones are a flight adaptation. Many bird bones have little marrow due to them being hollow. A bird's beak is primarily made of bone as projections of the mandibles which are covered in keratin. Some bones, primarily formed separately in subcutaneous tissues, include headgears (such as bony core of horns, antlers, ossicones), osteoderm, and os penis/os clitoris. A deer's antlers are composed of bone which is an unusual example of bone being outside the skin of the animal once the velvet is shed. The extinct predatory fish Dunkleosteus had sharp edges of hard exposed bone along its jaws. The proportion of cortical bone that is 80% in the human skeleton may be much lower in other animals, especially in marine mammals and marine turtles, or in various Mesozoic marine reptiles, such as ichthyosaurs, among others. This proportion can vary quickly in evolution; it often increases in early stages of returns to an aquatic lifestyle, as seen in early whales and pinnipeds, among others. It subsequently decreases in pelagic taxa, which typically acquire spongy bone, but aquatic taxa that live in shallow water can retain very thick, pachyostotic, osteosclerotic, or pachyosteosclerotic bones, especially if they move slowly, like sea cows.
=== Scurvy === Scurvy is a nutritional deficiency of water-soluble vitamin C or ascorbic acid. It is rare in the developing world and is mostly seen in infants, the elderly, and alcoholics, all who may have inadequate nutritional intake and malnutrition. Patients may present with general fatigue, weakness, poor wound healing, anemia, and gum disease. Clinically, one of the first signs of scurvy occurs on the skin and manifests as perifollicular hemorrhage where follicles of the skin are plugged with keratin. These areas appear as bruise-like spots around the hair follicles. There can also be fragile hairs arranged in a corkscrew confirmation. A lack of ascorbic acid leads to epigenetic DNA hypermethylation and inhibits the transcription of various types of collagen found in skin, blood vessels, and tissue.
Sources: en.wikipedia.org
from the Pliocene strata of Mininco Formation (Chile), extending known distribution of capybaras west of the Andes. Selvatici et al. (2026) determine a previously unidentified mummified animal from the Homestake Gulch site (Yukon, Canada) as a late Holocene (approximately 3000-years-old) New World porcupine, report the recovery of the first complete ancient mitochondrial genome of a member of this species, and interpret this finding as evidence of appearance of the New World porcupines in the studied area after the appearance of the boreal forest in the aftermath of the Last Glacial Period. Carrillo et al. (2026) study the evolutionary history of caviomorph rodents on the basis of data from extant and extinct members of the group, providing evidence of different trajectories of taxonomic and morphological diversification of Chinchilloidea and Octodontoidea. Evidence from the study of tooth wear of caviomorph rodents from the Paleogene strata of the Shapaja in Peruvian Amazonia, indicative of diverse dietary strategies of the studied rodents, is presented by Robinet et al. (2026). Gutstein et al. (2026) describe fossil material of a member of the genus Cardiatherium from the Bahía Inglesa Formation (Chile), providing evidence of wetter environmental conditions in the area of present-day Pacific coast of the Atacama Desert during the late Miocene. Delinschi et al. (2026) confirm the validity of Sarmatosminthus gabuniai on the basis of the analysis of fossil material from Vallesian sites in Moldova, Romania and Ukraine.
Moses Kacoul Machar (born 1945) was the Second Vice President of Sudan from February 2001 to January 2005. In 2004, he was sent abroad for medical treatment for an unspecified illness. Machar was also involved with talks with the Foreign Minister of Yemen, Abu Bakr al-Qerbi to forge a stronger relationship between the two countries. Before appointment as Vice President of Sudan, he was a professor in Juba University. In 2017 he was appointed to the South Sudanese National Dialogue steering committee.
== Background on native platelets == Native platelets play a vital role in hemostasis, the process of blood clotting and wound healing. Also known as thrombocytes, platelets are anucleate cell fragments derived from megakaryocytes in the bone marrow. Under healthy conditions, platelets circulate in an inactive state within the bloodstream and rapidly respond to vascular injury by initiating a complex cascade of coagulation events to prevent excessive blood loss. Native platelets are 2-3 micrometers in diameter and possess a highly specialized structure that enables their function in clot formation. Their cytoplasm contains dense granules and alpha granules, which store essential molecules such as adenosine diphosphate (ADP), serotonin, fibrinogen, and growth factors. These molecules are important for platelet activation, adhesion, and recruitment of additional platelets during vascular injury. The platelet membrane contains an abundance of glycoproteins, including integrins and receptors like glycoprotein Ib-IX-V and glycoprotein IIb/IIIa, which mediate interactions with the vascular endothelium and other platelets. A cytoskeleton composed of actin and tubulin allows platelets to change shape during activation, which extends filopodia to enhance adhesion and clot stability. Platelets engage in the following three-step process to form a stable blood clot: adhesion, activation, and aggregation.
== Pharmacokinetics in humans == A study was conducted to define the pharmacological response of humans to ractopamine. A single oral dose of 40 mg of ractopamine hydrochloride was given to human volunteers. The drug was rapidly absorbed; the mean blood plasma half-life was around 4 hrs and it was not detected in plasma 24 hrs after dosing. Less than 5% of total ractopamine excreted represented the parent drug, while the urinary metabolites were monoglucuronide and monosulfate conjugates, with ractopamine monosulfate being the major metabolite present. The metabolic fate of ractopamine hydrochloride is similar in the target species (pigs and cattle), laboratory animals, and humans. Besides the pharmacology effect, ractopamine may cause intoxication effect; therefore, any consumption by humans of a meat and/or byproducts of animals that consumed ractopamine with feed for growth stimulation, may result in such clinical effects as tachycardia and other heart rate increases, tremor, headache, muscle spasm, or high arterial blood pressure.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.